Sensorion

Company Overview

A French clinical-stage biotech focused exclusively on developing gene therapies and small-molecule treatments to restore, treat, and prevent hearing loss disorders across genetic and acquired etiologies. Sensorion targets both rare hereditary deafness caused by single-gene mutations and broader acquired hearing loss conditions, including sudden sensorineural hearing loss. The company positions itself at the intersection of audiology and precision medicine, leveraging gene therapy advances that have transformed adjacent rare disease fields. Its pipeline spans multiple clinical and preclinical programs addressing distinct biological causes of deafness.

Headquarters and Global Presence

Sensorion is headquartered in Montpellier, France, with scientific activities and collaborations centered in the Paris region through its partnership with Institut Pasteur. The company operates as a publicly listed entity on Euronext Paris and maintains an international clinical development footprint through its trial networks.

Founding and History

Sensorion was founded as a spin-out from INSERM, France's national biomedical research agency, with roots in inner-ear pharmacology research. The company built its early pipeline around small-molecule candidates before pivoting toward gene therapy as the strategic core of its hearing restoration ambitions. A significant leadership transition occurred in early 2026 when CEO Nawal Ouzren stepped down for personal reasons, with Fred Chereau appointed as her successor in May 2026. The company has completed multiple equity raises in recent years, securing over 110 million euros since mid-2024 to fund its gene therapy programs.

Therapy Areas and Focus

Sensorion focuses entirely on hearing loss, one of the world's most prevalent sensory disabilities, affecting approximately 1.5 billion people globally with no approved pharmacological or gene-based treatments for most forms. Its gene therapy programs target monogenic deafness caused by mutations in the OTOF gene, which encodes otoferlin, and the GJB2 gene, encoding connexin-26 — together among the most common causes of congenital profound deafness. The small-molecule program SENS-401 had addressed sudden sensorineural hearing loss and ototoxicity, though Phase II results announced in mid-2024 disappointed, prompting the strategic emphasis to shift firmly toward gene therapy. Unmet medical need in congenital deafness remains acute, with cochlear implants the only current standard of care and no biological restoration options approved.

Technology Platforms and Modalities

The company's primary platform employs adeno-associated virus vectors to deliver functional gene copies directly to cochlear hair cells — the sensory cells destroyed or dysfunctional in hereditary deafness — with the goal of restoring biological hearing rather than providing electronic substitutes. AAV-based delivery to the inner ear has attracted intense industry interest following proof-of-concept data from OTOF gene therapy trials globally, validating the cochlear gene therapy approach. Sensorion's manufacturing partnership with Novasep, a specialist life-sciences contract manufacturer, supports the production of clinical-grade AAV vectors at scale. A research collaboration with Institut Pasteur deepens the company's access to fundamental auditory neuroscience and next-generation vector optimization.

Key Pipeline and Programs

OTOF-GT is Sensorion's lead gene therapy candidate targeting otoferlin-related deafness, caused by biallelic mutations in the OTOF gene and resulting in profound congenital hearing loss from birth. Otoferlin is essential for synaptic vesicle fusion at inner hair cell ribbon synapses; its absence silences auditory signal transmission entirely. The program uses a dual-AAV vector strategy to accommodate the large OTOF coding sequence, a technical challenge the company has engineered solutions for in collaboration with Institut Pasteur. The program has drawn Regulatory interest, with Sensorion shares rising 17% in June 2024 following an FDA designation announcement related to the hearing loss pipeline.

GJB2-GT targets connexin-26 deficiency, the single most common cause of hereditary hearing loss worldwide, caused by mutations in the GJB2 gene. Connexin-26 forms gap junctions in cochlear supporting cells critical for potassium recycling; disruption collapses the electrochemical environment needed for hair cell function. This program remains in earlier development but represents a large addressable patient population given GJB2's prevalence across all ethnicities.

SENS-401, a small-molecule radicicol analogue with anti-inflammatory and hair-cell-protective properties, was evaluated in Phase II for sudden sensorineural hearing loss but missed its primary endpoints, a setback disclosed in June 2024 that triggered a 42% share price decline. The asset's future role in the portfolio is limited following that readout.

Recent Developments

In January 2026, Sensorion completed a reserved equity offering raising 60 million euros ($65 million), led by Sanofi with a 20 million euro anchor investment — a significant vote of confidence from France's largest pharma company and a signal of the gene therapy pipeline's credibility. The financing followed a 50.5 million euro raise in June 2024, giving the company a combined capital injection exceeding 110 million euros across 18 months. A leadership transition unfolded in early 2026, with CEO Nawal Ouzren departing in February and Fred Chereau formally appointed as the new chief executive in May 2026. In mid-2024, Sensorion also formalized its manufacturing deal with Novasep and its research collaboration with Institut Pasteur, establishing the two pillars of its gene therapy supply and science infrastructure.

Key Personnel

Fred Chereau serves as Chief Executive Officer, appointed in May 2026 following Nawal Ouzren's departure. Chereau brings leadership experience in European biotech and life sciences, taking the helm as Sensorion transitions its strategy fully toward gene therapy delivery. The company's scientific direction is shaped through its institutional collaboration with Institut Pasteur's hearing and auditory neuroscience expertise in Paris.

Strategic Partnerships

Sanofi anchored Sensorion's January 2026 equity raise with a 20 million euro investment, establishing France's pharma flagship as a key financial backer and potential strategic ally in the hearing gene therapy space. The manufacturing agreement with Novasep covers AAV vector production and development services, providing Sensorion with a domestic French supply chain for clinical-grade gene therapy materials. The Institut Pasteur collaboration underpins the scientific foundations of Sensorion's gene therapy programs, offering access to world-class auditory biology research and potentially novel vector approaches.

FAQ Section